Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Renal Society of Australasia Journal, published by the Renal Society of Australasia, serves as a crucial platform for disseminating cutting-edge research and insights within the fields of nephrology and urology. With its ISSN of 1832-3804, this journal has been continually published since 2011, showcasing the evolving landscape of renal health in Australia and beyond. Despite currently holding a Q4 ranking in both nephrology and urology categories, the journal is committed to supporting the scientific community with rigorous peer-reviewed articles that enhance clinical practice and foster research advancement. As an open access journal, it aims to provide wide visibility and access to researchers, professionals, and students alike, thus promoting knowledge sharing among various stakeholders in renal health. Positioned within a global context, it addresses local health challenges while contributing to the broader discourse in renal sciences, making it an essential resource for those dedicated to improving patient outcomes in this critical area of medicine.

CEN Case Reports is an influential journal published by Springer Japan KK, dedicated to advancing the knowledge and understanding of case reports across various scientific disciplines. The journal, identified by ISSN 2192-4449, focuses on disseminating high-quality, peer-reviewed case studies that illuminate unique clinical phenomena and contribute to the broader medical and scientific communities. Since its inception in 2018, CEN Case Reports has strived to provide a platform for researchers, professionals, and students to share groundbreaking findings while fostering collaborations across the globe. Although the journal currently does not adopt an open access model, it remains committed to accessibility through institutional subscriptions and individual purchase options. With a growing repository of insightful case reports, this journal plays a crucial role in enriching the evidence-based approach to medical practice and research, ensuring its relevance in a rapidly evolving field.

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.

Renal Replacement Therapy is an esteemed open-access journal published by BMC, dedicated to advancing the field of nephrology, transplantation, and urology. Established in 2015, the journal aims to disseminate high-quality research findings to enhance the understanding and management of kidney-related diseases and therapies. Renal Replacement Therapy is ranked in the third quartile (Q3) in the categories of Nephrology, Transplantation, and Urology as of 2023, reflecting its growing influence and commitment to academic excellence. The journal encourages interdisciplinary study and collaboration, welcoming contributions from researchers, clinicians, and healthcare professionals. With a focus on practical applications and innovative therapies, this journal is instrumental for those seeking the latest insights and advancements in renal replacement strategies. Located in the United Kingdom, the journal strives to provide unparalleled access to critical research, ensuring that its findings are available to a global audience striving to improve patient outcomes in renal health.

Case Reports in Nephrology and Dialysis, published by KARGER, is a vital peer-reviewed journal dedicated to the dissemination of case reports and innovative findings in the fields of nephrology and dialysis. Since its inception in 2015, this Open Access journal has aimed to foster knowledge exchange and improve patient outcomes through comprehensive case studies, clinical insights, and recent advancements in renal healthcare. Based in Switzerland, the journal is poised to serve a global audience, accommodating research that spans diverse geographical and clinical contexts. Currently ranked in the Q3 category for nephrology in 2023, it underscores its burgeoning influence in the medical literature, despite its relatively nascent presence. As a valuable resource for researchers, healthcare professionals, and students, it provides a platform for sharing unique cases that enrich the understanding of complex renal issues and challenges faced in dialysis. With an emphasis on high-quality, accessible research, Case Reports in Nephrology and Dialysis is committed to advancing nephrology and dialysis practices through collaboration and knowledge sharing.

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.